SCHEMBL311619

SCHEMBL311619

Fc1ccc(-c2c[nH]c(C3CCNCC3)n2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MKNK1 Q9BUB5 1/20 0.54
MKNK2 Q9HBH9 1/20 0.54
MAPK11 Q15759 2/20 0.50
MAPK14 Q16539 2/20 0.50
MAPK13 O15264 1/20 0.50
RAF1 P04049 1/20 0.50
MAPK9 P45984 1/20 0.50
MAPK12 P53778 1/20 0.50
PLAT P00750 2/20 0.43
HTR2A P28223 1/20 0.41
HTR2C P28335 1/20 0.41
HTR2B P41595 1/20 0.41
HTR1A P08908 2/20 0.38
SLC6A2 P23975 2/20 0.38
SLC6A4 P31645 2/20 0.38
SLC6A3 Q01959 2/20 0.38
JAK2 O60674 1/20 0.38
JAK3 P52333 1/20 0.38
PTK2 Q05397 1/20 0.38
TNKS O95271 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15824768 0.91 PTGS1 (0.43) MKNK1MKNK2MAPK11MAPK14MAPK13
Tert-Butyl Formate SCHEMBL27507421 0.86 MKNK1 (0.42) MKNK1MKNK2MAPK11MAPK14MAPK13
SCHEMBL15732671 0.85 APP (0.44) MKNK1MKNK2MAPK11MAPK14MAPK13
SCHEMBL27776218 0.85 HTR3A (0.46) MKNK1MKNK2HTR2AHTR2CHTR2B
SCHEMBL6166041 0.85 SLC18A3 (0.47) HTR2AHTR2C
SCHEMBL312409 0.84 SLC18A3 (0.50) HTR2AHTR2C
SCHEMBL15732539 0.84 HTR2C (0.56) PLATHTR2CHTR1ASLC6A2SLC6A4
Hydrochloric Acid SCHEMBL15732595 0.84 HTR3A (0.45) MKNK1MKNK2MAPK11MAPK14MAPK13
Hydrochloric Acid SCHEMBL6806273 0.84 SLC18A3 (0.46) HTR2AHTR2C
Hydrochloric Acid SCHEMBL1653372 0.83 SLC18A3 (0.49) HTR2AHTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1349850-B1 SODIUM CHANNEL MODULATORS DERIVED FROM 2-PIPERIDYLIMIDAZOLES SOD CONSEILS RECH APPLIC (FR) 2005-09-07 EP claimed
CN-1214025-C Sodium channel modulators derived from 2-piperidylimidazoles SOD CONSEILS RECH APPLIC (FR) 2005-08-10 CN claimed
CN-1483029-A Sodium channel modulators derived from 2-piperidylimidazoles ��ѧ�о���Ӧ����ѯ��˾ 2004-03-17 CN claimed
EP-1349850-A1 SODIUM CHANNEL MODULATORS DERIVED FROM 2-PIPERIDYLIMIDAZOLES Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) (FR) 2003-10-08 EP claimed
WO-2002053559-A1 SODIUM CHANNEL MODULATORS DERIVED FROM 2-PIPERIDYLIMIDAZOLES SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2002-07-11 WO claimed
EP-2148880-B1 P70 S6 KINASE INHIBITORS LILLY CO ELI (US) 2014-05-28 EP disclosed
CN-101679439-B P70S 6 kinase inhibitors LILLY CO ELI 2013-09-11 CN disclosed
US-20120071490-A1 P70 S6 KINASE INHIBITORS ELI LILLY AND COMPANY (US) 2012-03-22 US disclosed
US-8093383-B2 P70 S6 kinase inhibitors ELI LILLY AND COMPANY (US) 2012-01-10 US disclosed
CN-101679439-A P70S 6 kinase inhibitors LILLY CO ELI 2010-03-24 CN disclosed
US-20090163714-A1 P70 S6 KINASE INHIBITORS ELI LILLY AND COMPANY 2009-06-25 US disclosed
EP-1349850-B1 SODIUM CHANNEL MODULATORS DERIVED FROM 2-PIPERIDYLIMIDAZOLES SOD CONSEILS RECH APPLIC (FR) 2005-09-07 EP disclosed
CN-1214025-C Sodium channel modulators derived from 2-piperidylimidazoles SOD CONSEILS RECH APPLIC (FR) 2005-08-10 CN disclosed
US-20040077640-A1 Sodium channel modulators derived from 2-piperidylimidazoles SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2004-04-22 US disclosed
CN-1483029-A Sodium channel modulators derived from 2-piperidylimidazoles ��ѧ�о���Ӧ����ѯ��˾ 2004-03-17 CN disclosed
EP-1349850-A1 SODIUM CHANNEL MODULATORS DERIVED FROM 2-PIPERIDYLIMIDAZOLES Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) (FR) 2003-10-08 EP disclosed
WO-2002053559-A1 SODIUM CHANNEL MODULATORS DERIVED FROM 2-PIPERIDYLIMIDAZOLES SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2002-07-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040077640-A1 Sodium channel modulators derived from 2-piperidylimidazoles KCNH1, HCN4, KCNH2 MKNK1 2169/4885MKNK2 2517/4885MAPK11 2742/4885
US-20090163714-A1 P70 S6 KINASE INHIBITORS RPS6KA6, RPS6KA1, RPS6KA2 MKNK1 121/4885MKNK2 92/4885MAPK11 475/4885
US-20120071490-A1 P70 S6 KINASE INHIBITORS RPS6KA6, RPS6KA1, RPS6KA2 MKNK1 121/4885MKNK2 92/4885MAPK11 475/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.